| abstract |
The present invention relates to peptides, proteins, nucleic acids and cells for use in nimmunotherapeutic methods. In particular, the present invention relates to the nimmunotherapy of cancer. The present invention furthermore relates to tumornassociated T-cell peptide epitopes, alone or in combination with other tumornassociated peptides that can for example serve as active pharmaceutical ingredients nof vaccine compositions that stimulate anti-tumor immune responses, or to stimulate nT cells ex vivo and transfer into patients. Peptides bound to molecules of the major nhistocompatibility complex (MHC), or peptides as such, can also be targets of nantibodies, soluble T-cell receptors, and other binding molecules. |